Zylox-Tonbridge Medical Technology Co (HKSE:02190) Debt-to-EBITDA : -0.66 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zylox-Tonbridge Medical Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$59.1 Mil. Zylox-Tonbridge Medical Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2.0 Mil. Zylox-Tonbridge Medical Technology Co's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-92.4 Mil. Zylox-Tonbridge Medical Technology Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.66.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:02190' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.34 Med: -0.38 Max: -0.05
Current: -0.73

During the past 5 years, the highest Debt-to-EBITDA Ratio of Zylox-Tonbridge Medical Technology Co was -0.05. The lowest was -1.34. And the median was -0.38.

HKSE:02190's Debt-to-EBITDA is ranked worse than
100% of 433 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs HKSE:02190: -0.73

Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Chart

Zylox-Tonbridge Medical Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.42

-0.38

-0.05

-0.16

-1.34

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial				-0.04	-0.23	-0.08	-0.28	-0.66

Competitive Comparison of Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA

For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA falls into.

Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(59.084	+	2.033)	/	-45.504
	=	-1.34

Zylox-Tonbridge Medical Technology Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(59.084	+	2.033)	/	-92.392
	=	-0.66

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Zylox-Tonbridge Medical Technology Co (HKSE:02190) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Zylox-Tonbridge Medical Technology Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Zylox-Tonbridge Medical Technology Co (HKSE:02190) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (HKSE:02190) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 18 Keji Avenue, Yuhang Street, 1st & 2nd Floors, Building 1, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.zyloxtb.com

Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries.

Executives

Gan Zhou Ti Tan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2501 Other
Su Zhou Tai Hong Jing Hui Tou Zi Zhong Xin You Xian He Huo	2501 Other
Five Investment Limited	2501 Other
Highlight Medical Limited	2501 Other
Ourea Biotech Hk Limited	2501 Other
Wang Stephen Hui	2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Tie Si Yi Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2501 Other
Jia Jian Tou Zi You Xian Gong Si	2501 Other
Wea Enterprises ,llc	2401 A concert party to an agreement to buy shares
Hu Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Ning Bo Gui Qiao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Zhu Hai Gui Chuang Gu Quan Tou Zi Zhong Xin You Xian He Huo	2401 A concert party to an agreement to buy shares
Hang Zhou Fu Jiang Tou Zi He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Zhu Hai Tong Qiao Tou Zi Zhong Xin You Xian He Huo	2401 A concert party to an agreement to buy shares
Li Zheng	2501 Other

Zylox-Tonbridge Medical Technology Co (HKSE:02190) Headlines

No Headlines